These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Role of technology assessment in health benefits coverage for medical devices. Braslow NM; Shatin D; McCarthy DB; Newcomer LN Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990 [TBL] [Abstract][Full Text] [Related]
26. Economic data transferability for HTA: are we there yet? Manca A Value Health; 2009 Jun; 12(4):407. PubMed ID: 19900247 [No Abstract] [Full Text] [Related]
27. The role of cost-effectiveness analysis in health care decision-making. Magel JS Physician Exec; 1990; 16(3):31-2. PubMed ID: 10113233 [TBL] [Abstract][Full Text] [Related]
28. Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective. Forster M; Pertile P Health Econ; 2013 Dec; 22(12):1507-14. PubMed ID: 23225192 [TBL] [Abstract][Full Text] [Related]
29. Wise buys. Freemantle N Health Serv J; 1992 Jan; 102(5285):23. PubMed ID: 10116994 [No Abstract] [Full Text] [Related]
31. Is high-tech treatment worth the cost? Kastiel DL Bus Insur; 1985 Nov; 19(44):30. PubMed ID: 10274034 [No Abstract] [Full Text] [Related]
32. Health technology assessment in Europe. Kristensen FB Scand J Public Health; 2009 Jun; 37(4):335-9. PubMed ID: 19493989 [No Abstract] [Full Text] [Related]
33. Technology assessment and the doctor-patient relationship. Wax AL Va Law Rev; 1996 Nov; 82(8):1641-62. PubMed ID: 16715567 [No Abstract] [Full Text] [Related]
34. Health technology assessment and clinical decision making: which is the best evidence? Granados A Int J Technol Assess Health Care; 1999; 15(3):585-92. PubMed ID: 10874384 [TBL] [Abstract][Full Text] [Related]
36. EXPANDING EVIDENCE-BASED TECHNOLOGY ASSESSMENT FOR COVERAGE IN WASHINGTON STATE. Landaas EJ; Franklin G; Thompson J; Lessler D; Morse J; Mootz R; Hammond SG; Sullivan SD Int J Technol Assess Health Care; 2016 Jan; 32(3):140-6. PubMed ID: 27491675 [TBL] [Abstract][Full Text] [Related]
37. Health technology assessment in the cost-disutility plane. Eckermann S; Briggs A; Willan AR Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312 [TBL] [Abstract][Full Text] [Related]
38. Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines. Ghabri S; Cleemput I; Josselin JM Pharmacoeconomics; 2018 Feb; 36(2):127-130. PubMed ID: 29264865 [No Abstract] [Full Text] [Related]
39. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Jönsson B Eur J Health Econ; 2009 Oct; 10(4):357-9. PubMed ID: 19618224 [No Abstract] [Full Text] [Related]
40. Introducing the JME special issue on cost-effectiveness analyses. Lee K J Med Econ; 2012; 15 Suppl 1():1-2. PubMed ID: 23163333 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]